Acta medica Indonesiana
-
In the past 10 years, recent development of targeted therapy in metastatic renal cell carcinoma (mRCC) has provided a new hope and significantly enhanced the prognosis of the disease. Three class of targeted therapy were developed, including multi-targeted tyrosine kinase inhibitors (TKI), the mammalian target of rapamycin (mTOR) complex-1 kinase inhibitors, and the humanized antivascular endothelial growth factor (VEGF) monoclonal antibody. Hence, the objective of this article was to critically examine the current evidence of targeted therapy treatment for patients with mRCC. ⋯ However, the current evidence did not show the best treatment sequencing after first-line TKI failure. In patients with poor-risk clear-cell and non-clear cell mRCC, temsirolimus was the treatment option supported by phase III clinical trial. In addition, several new drugs, nowadays, are still being investigated and waiting for the result of phase II or III clinical trial, and this might change the standard therapy for mRCC in the future.
-
Acta medica Indonesiana · Oct 2016
Short-term Survival of Acute Respiratory Distress Syndrome Patients at a Single Tertiary Referral Centre in Indonesia.
to identify the 28-day short-term survival rate in patients with acute respiratory distress syndrome (ARDS). ⋯ the short-term survival rate of ARDS in developing countries including Indonesia is still low and early management with optimal treatment provided within the first week may improve the survival rate.